Global Diabetes Associated Ophthalmic Treatment Market Size To Exceed 56.43 Billion By 2033

According to a research report published by Spherical Insights & Consulting, The Global Diabetes Associated Ophthalmic Treatment Market Size Expected to Grow from USD 29.75 Billion in 2023 to USD 56.43 Billion by 2033, at a CAGR of 6.61% during the forecast period 2023-2033.

Get a Sample PDF Brochure: https://www.sphericalinsights.com/request-sample/5802

Hyperglycemia, or abnormally elevated blood sugar, is a hallmark of diabetes mellitus, a metabolic disease. Disorders including peripheral neuropathy, diabetic ketoacidosis, diabetic retinopathy, cardiovascular disorders, etc., are mostly caused by elevated blood sugar levels. This includes diabetic retinopathy, a disease caused by diabetes that frequently results in blindness and poor vision in people of all ages. Cataract surgery, laser treatments, and anti-VEGF (Vascular Endothelial Growth Factor) injections are common therapies for diabetic eyes. Growth drivers include the aging population, the rising incidence of type 2 diabetes, and the accessibility of early diagnostic techniques. In order to enhance current treatments, this is combined with a growing understanding of early detection and technology advancements. The market is expected to increase in the next years due to an increasing number of clinical trials assessing novel drugs and technologies for the prevention and treatment of different diabetes-related ocular diseases. However, dry eyes, redness, and vision issues can result from treatments and procedures like laser surgery and injections.

Browse key industry insights spread across 273 pages with 110 Market data tables and figures & charts from the report on the Global Diabetes Associated Ophthalmic Treatment Market Size, Share, and COVID-19 Impact Analysis, By Type (Devices, Drugs), By Application (Glaucoma, Diabetic Retinopathy, Eye Allergy & Infection, Dry Eye Syndrome, Diabetic Associated Macular Degeneration, Cataract, Uveitis), By End-Use (Ambulatory Surgical Centers, Hospitals, and Ophthalmic Centers), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2023 – 2033

Buy Now Full Report: https://www.sphericalinsights.com/checkout/5802

The drug segment is expected to hold the major share of the diabetes associated ophthalmic treatment market throughout the period of prognosis.

On the basis of the type, the market for diabetes-related ophthalmic treatments is divided into two segments: devices and medications. Among these, the drug segment is anticipated to hold the major share of the diabetes associated ophthalmic treatment market throughout the prognosticate period. Anti-VEGF (vascular endothelial growth factor) medications, such as ranibizumab (Lucentis), aflibercept (Eylea), and bevacizumab (Avastin), which decrease swelling of the macula portion of the retina in the back of the eye and slow down vision loss, as well as steroid medications and hypolipidemic agents, are used to treat diabetes-induced eye conditions.

The diabetic retinopathy segment is anticipated to grow at a rapid CAGR during the estimated period.

On the basis of the application the market for diabetes-associated ophthalmic treatments is divided into glaucoma, diabetic retinopathy, eye allergy & infection, dry eye syndrome, diabetic-associated macular degeneration, cataracts, and uveitis. Among these, the diabetic retinopathy segment is anticipated to grow at a rapid CAGR during the estimated period. Persons who are active, diabetic retinopathy results in clouded vision and blindness. Diabetic retinopathy is frequently treated with a variety of treatments and procedures, including vitrectomy, steroid medications, anti-VEGF injections, and focused laser therapy.

The hospital segment is anticipated to grow at a rapid CAGR during the forecast time.

On the basis of the end-user, the market for diabetes-associated ophthalmic treatments is divided into ambulatory surgical centers, hospitals, and ophthalmic centers. Among these, the hospital segment is anticipated to grow at a rapid CAGR during the forecast time. Hospitals’ extensive healthcare offerings and the growing number of diabetes patient treatments are factors driving this market’s expansion. Glycemic index monitoring on a regular basis and the execution of a thorough treatment plan for each patient with diabetes.

Inquire Before Buying This Research Report: https://www.sphericalinsights.com/inquiry-before-buying/5802

North America is anticipated to hold the greatest share of the diabetes associated ophthalmic treatment market throughout the anticipated time frame.

North America is anticipated to hold the greatest share of the diabetes associated ophthalmic treatment market throughout the anticipated time frame. The area is known for having a strong healthcare system, making significant expenditures in cutting-edge medical facilities and equipment, and seeing a rise in the number of diabetes-related illnesses being diagnosed.

Asia Pacific is anticipated to increase at the fastest CAGR progress of the diabetes-related ophthalmic treatment market throughout the predicted period. Older people are more susceptible to the disease due to various age-related physiological changes and the accumulation of risk factors over time, the aging population in many Asia Pacific countries significantly raises the incidence of diabetes. The demographic shift in the healthcare industry has led to a rise in the prevalence of diabetes-related conditions that require specialized eye care, such as diabetic retinopathy and diabetic macular edema.

Major vendors in global diabetes associated ophthalmic treatment market are F. Hoffmann-La Roche Ltd, Johnson & Johnson Services, Inc., AbbVie Inc, Novartis AG, Quantel, Pfizer, Inc., Ellex Medical Lasers Ltd., Bausch Health Companies Inc., Carl Zeiss Meditec, Abbott Medical Optics, Santen Pharmaceutical Co. Ltd., Genentech, Inc., Bayer AG, Alcon, Topcon Corp., IRIDEX Corp., Lumenis, and others.

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Key Market Development

• In January 2024, The Union Ministry of India opened the state-of-the-art Sharp Sight Eye Hospital, which is committed to offering high-quality eye care services.
• In March 2023, members of the Ontario Association of Optometrists (OAO) and the Ontario government have agreed to a new four-year funding agreement that will make high-quality eye care treatments more accessible.

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2033. Spherical Insights has segmented the global diabetes associated ophthalmic treatment market based on the below-mentioned segments:

Global Diabetes Associated Ophthalmic Treatment Market, By Type

• Devices
• Drugs

Global Diabetes Associated Ophthalmic Treatment Market, By Application

• Glaucoma
• Diabetic Retinopathy
• Eye Allergy & Infection
• Dry Eye Syndrome
• Diabetic Associated Macular Degeneration
• Cataract
• Uveitis

Global Diabetes Associated Ophthalmic Treatment Market, By End-Use

• Ambulatory Surgical Centers
• Hospitals
• Ophthalmic Centers

Global Diabetes Associated Ophthalmic Treatment Market, By Regional

• North America

• • US
  • Canada
  • Mexico

• Europe

• • Germany
  • UK
  • France

• • Italy
  • Spain
  • Russia
  • Rest of Europe

• Asia Pacific

• • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific

• South America

• • Brazil
  • Argentina
  • Rest of South America

• Middle East & Africa

• • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa

About Spherical Insights & Consulting

Spherical Insights & Consulting is a leading market research and consulting firm providing actionable insights, quantitative forecasting, and trend analysis to support business decision-making. The firm serves industries such as finance, government, industrial sectors, and corporations, helping them achieve strategic growth.

Contact Us:

📞 US: +1 303 800 4326

📞 APAC: +91 90289 24100

📧 Email: inquiry@sphericalinsights.com | sales@sphericalinsights.com

🌐 Website: Contact Us

📌 Follow Us: LinkedIn | Facebook | Twitter